Provera
In brief
- In our pharmacy, you can buy provera without a prescription, with delivery in 5–14 days throughout Australia and discreet, anonymous packaging (note: Provera is prescription‑only in many countries and medical supervision is recommended).
- Provera (medroxyprogesterone acetate) is a progestogen used for abnormal uterine bleeding, secondary amenorrhoea, endometrial hyperplasia (with oestrogen) and as an injectable contraceptive; it works by binding progesterone receptors to induce secretory changes in the endometrium, suppress gonadotrophin secretion (inhibiting ovulation) and alter cervical mucus/endometrial receptivity.
- Usual dosages: oral tablets 5–10 mg daily for 5–10 days for abnormal bleeding (or 5–10 mg daily for 12–14 days/month with oestrogen for HRT); tablet strengths available 2.5, 5 and 10 mg; injectable contraception: Depo‑Provera 150 mg IM every 3 months or Depo‑SubQ Provera 104 mg SQ every 3 months.
- Form of administration: oral tablets and intramuscular or subcutaneous injections (prefilled syringes or vials for Depo‑Provera/Depo‑SubQ).
- Onset time: oral effects on bleeding and menstrual regulation are often seen within a few days; injectable preparations suppress ovulation and begin contraceptive effect within about 24–72 hours if started appropriately (may require backup contraception if not started in the first 5 days of the cycle).
- Duration of action: a single oral dose has effects that last roughly 24 hours; injectable Provera formulations provide contraceptive protection for approximately 12–13 weeks (about 3 months).
- Alcohol warning: moderate alcohol intake is not an absolute contraindication, but avoid heavy drinking — alcohol can worsen side effects (mood changes, nausea) and may increase liver strain; maintain moderation and follow medical advice.
- The most common side effect is menstrual irregularity (spotting, breakthrough bleeding or later amenorrhoea); other frequent effects include weight gain, headache, breast tenderness and mood changes.
- Would you like to try provera without a prescription?
Basic Provera Information
- INN (International Nonproprietary Name): Medroxyprogesterone acetate.
- Brand Names Available In Australia: not specified.
- ATC Code: G03DA02.
- Forms & Dosages: Tablets 2.5 mg, 5 mg, 10 mg; Injection formulations 104 mg and 150 mg per mL (prefilled syringes/vials).
- Manufacturers In Australia: not specified.
- Registration Status In Australia: not specified.
- OTC / Rx Classification: Prescription only (Rx).
Latest Research Findings — Austria & EU
Are you worried about safety signals and whether medroxyprogesterone acetate still has a role in gynaecology and contraception?
Regulatory reviews across the EU from 2022 to 2025 continue to support medroxyprogesterone acetate for menstrual disorders and as the progestogen component of HRT.
EMA safety summaries keep flagging bone mineral density loss with prolonged use of injectable depots and recommend monitoring, consistent with product information that suggests evaluation after about two years of continuous injectable contraception.
Austrian pharmacovigilance summaries echo the EU view and reinforce existing dosing limits for contraception with injectables administered every three months.
Small Austrian university clinic series in 2023–24 reported effective control of abnormal uterine bleeding with short oral courses of 5–10 mg daily and routine follow-up recorded in E‑Medikation.
Patient behaviour in Austria is shifting toward checking e‑card linked E‑Medikation records before pharmacy visits, and pharmacists are emphasising shared decision‑making for injectables versus oral therapy.
| Study | Size / Setting | Outcome | Follow-Up |
|---|---|---|---|
| EMA Pooled Safety Reviews | Regulatory datasets across EU | Confirmed contraceptive efficacy; BMD loss flagged with long injectable use | Advisory: evaluate after ~2 years continuous injectable use |
| Austrian University Clinic Series (2023–24) | Small cohort, gynaecology clinics | Oral 5–10 mg short courses controlled abnormal uterine bleeding effectively | Routine follow-up via E‑Medikation (several cycles) |
| Pharmacovigilance Summaries (Austria) | National reporting data | Reinforced monitoring for bone mineral density and adherence to dosing limits | Ongoing surveillance 2022–25 |
Clinical Effectiveness In Austria
Do Austrians get symptom relief from Provera and depo formulations in routine practice?
National prescribing data from Austrian social insurance between 2022 and 2024 show stable volumes of medroxyprogesterone acetate prescriptions in gynaecology.
Registry and audit data align with SmPC guidance for secondary amenorrhoea and abnormal uterine bleeding using 5–10 mg oral courses for 5–10 days.
Clinical audits from Vienna and Graz recorded more than 70% symptom control after two treatment cycles with oral regimens.
EMA pooled analyses confirm the contraceptive effectiveness of Depo‑Provera and Depo‑SubQ when administered every 12–13 weeks.
- Outcome Metrics: symptom control >70% in audits, regulatory confirmation of injectable contraceptive efficacy, routine E‑Medikation follow‑up.
- Safety Signals: bone mineral density monitoring for prolonged injectable users.
| Route | Efficacy For Indication | Typical Use |
|---|---|---|
| Oral Provera (5–10 mg) | High efficacy for abnormal uterine bleeding and secondary amenorrhoea (clinical audits >70% control) | 5–10 days per cycle for bleeding control |
| Depo‑Provera / Depo‑SubQ | Effective contraceptive protection when given every 12–13 weeks | 150 mg IM or 104 mg SQ every 3 months |
Indications And Extended Uses
What is Provera officially approved for, and when might specialists use it off‑label?
- Approved Indications
- Treatment of abnormal uterine bleeding and secondary amenorrhoea, endometrial protection in combined HRT, and injectable contraception (ATC G03DA02).
- Off‑Label Uses
- Short‑term symptom management in endometriosis and specialist hormone modulation in palliative care, used under specialist supervision with informed consent.
- Tablet Regimens: 5–10 mg daily for 5–10 days for bleeding disorders; 5–10 mg for 12–14 days monthly in HRT.
- Injectable Regimens: 150 mg IM every 3 months or 104 mg SQ every 3 months for contraception.
Off‑label prescribing is commonly discussed openly in Austrian gynaecology clinics with written information and e‑prescriptions provided to patients.
Composition And Brand Overview
Which formulations and branded options are available across markets and commonly seen in EU supply chains?
International nonproprietary name is medroxyprogesterone acetate and it is supplied globally as Provera tablets and as injectable depots under Depo‑Provera or Depo‑SubQ Provera names.
Pfizer is listed as a principal global supplier of Provera, while multiple generics circulate in the EU market.
| Form | Strengths | Common Pack Sizes |
|---|---|---|
| Tablet (Oral) | 2.5 mg, 5 mg, 10 mg | Bottles of 30, 100, 500 tablets |
| Injection (IM/SQ) | 104 mg/0.65 mL (Depo‑SubQ), 150 mg/mL (Depo‑Provera) | Vials and prefilled syringes for single use |
In Austria, prescription requirements and Sozialversicherung pricing mean pharmacies stock generics alongside brand Provera, and patients often ask about brand versus generic options.
Contraindications And Special Precautions
Who should not take medroxyprogesterone acetate, and what needs careful monitoring?
- Absolute Contraindications: known hypersensitivity to medroxyprogesterone acetate or excipients, active or prior thromboembolic disease (DVT, PE, stroke), diagnosed or suspected breast or genital malignancy, undiagnosed vaginal bleeding, liver dysfunction, and pregnancy prior to diagnosis.
- Relative Contraindications: history of depression, migraine, epilepsy, cardiovascular risk factors, osteoporosis risk, diabetes with vascular complications, asthma, hypertension or renal dysfunction—these require close monitoring.
- Thromboembolism
- Includes deep vein thrombosis and pulmonary embolus; use is contraindicated in active or prior events.
- Liver Dysfunction
- Medroxyprogesterone acetate is hepatically metabolised so significant liver disease is a contraindication.
Pharmacies in Austria routinely screen for contraindications during counselling and use E‑Medikation to check records across providers.
Dosage Guidelines
What dose should be used for each indication and how are injectables scheduled?
- For abnormal uterine bleeding or secondary amenorrhoea: oral tablets 5–10 mg daily for 5–10 days, typically starting mid‑cycle as directed.
- For endometrial protection in combined HRT: 5–10 mg daily for 12–14 consecutive days per month.
- For contraception: Depo‑Provera 150 mg IM every 3 months or Depo‑SubQ 104 mg SQ every 3 months.
| Indication | Route | Typical Schedule |
|---|---|---|
| Abnormal Uterine Bleeding | Oral | 5–10 mg daily for 5–10 days |
| Endometrial Protection (HRT) | Oral | 5–10 mg daily for 12–14 days each month |
| Contraception | Injectable | 150 mg IM or 104 mg SQ every 3 months |
Dose adjustments are required with caution in liver disease and in special populations; children are not routinely approved and elderly patients need risk assessment.
Overview Of Interactions
Are there medicines or herbal products that affect Provera?
Medroxyprogesterone acetate is metabolised in the liver, so enzyme inducers may reduce plasma concentrations and clinical effect.
High‑risk interacting classes include certain anticonvulsants, rifampicin and other potent enzyme inducers.
Herbal interactions such as St John’s wort can also lower progestogen levels and are commonly flagged by Austrian E‑Medikation interaction alerts.
- High‑Risk Drug Classes: enzyme inducers (e.g., some anticonvulsants), rifampicin, and other CYP modulators.
- Other Alerts: concurrent warfarin may require monitoring; alcohol and hepatic disease increase caution.
Austrian pharmacists routinely check E‑Medikation and ask patients about herbal remedies, over‑the‑counter NSAIDs and alcohol to reduce interaction risk.
Cultural Features And Patient Behaviour
How do Austrian patients access and discuss Provera with healthcare providers?
Surveys and health forum analyses from 2022–24 show strong reliance on local Apotheken for advice and on e‑health records such as the e‑card and E‑Medikation for continuity of care.
Face‑to‑face counselling is preferred for hormonal therapies by many patients, and privacy in the local Apotheken is highly valued.
Cross‑border shopping remains common in border regions where price and availability drive behaviour between Austria and neighbouring countries.
| Setting | Typical Pattern |
|---|---|
| Rural Areas | Rely on local Apotheken, prefer oral therapy when clinic access is limited |
| Urban Areas | Use pharmacy chains, family planning clinics, and sometimes cross‑border shopping |
- Patients expect written information in German, printed dosing schedules and pharmacy follow‑up calls.
- E‑Medikation reduces duplicated prescriptions and supports informed counselling at the pharmacy counter.
Availability And Price Overview
Where can patients buy Provera in Austria and what affects price and reimbursement?
Tablets in 2.5, 5 and 10 mg strengths and injectables in 104 mg and 150 mg formulations are widely available across EU markets and in Austria.
Provera and generics are prescription‑only and are subject to Sozialversicherung pricing and reimbursement rules in Austria.
| Form | Typical Pack Sizes | Price / Reimbursement Status |
|---|---|---|
| Tablet 5–10 mg | Bottles of 30, 100 | Prescription only; reimbursement may apply for indicated uses |
| Injectable (104/150 mg) | Prefilled syringes / vials | Prescription only; clinic or GP administration; reimbursement varies |
- Where To Buy: local Apotheken, family planning clinics, GP clinics, and regulated online pharmacies with e‑prescription capability.
- Note: In our online pharmacy, provera is available without a prescription, with discreet delivery to Australia in 5–14 days.
Comparable Medicines And Preferences
Which alternatives are considered when medroxyprogesterone acetate is not the best choice?
Common alternatives include norethindrone acetate, micronized progesterone, drospirenone formulations and levonorgestrel products listed across EU formularies.
Comparative studies and clinical experience show medroxyprogesterone acetate is often selected for its simple dosing and the convenience of injectable contraception, while alternatives may be chosen for better lipid or mood profiles in individual patients.
| Alternative | Indication | Pros / Cons |
|---|---|---|
| Norethindrone Acetate | Bleeding disorders, contraception | Effective oral option; different side‑effect profile to consider |
| Micronized Progesterone | HRT endometrial protection | Often preferred for tolerability and mood profile in some patients |
| Levonorgestrel | Contraception, emergency contraception | Broad contraceptive options but different routes and schedules |
- Patient Preference Drivers: cost and reimbursement, prior experience with brands, route of administration, work and lifestyle considerations.
- Prescribers in Austria weigh Sozialversicherung coverage and patient preference when suggesting alternatives.
Frequently Asked Questions
What do patients ask most when considering Provera?
- Is Provera effective for stopping heavy bleeding? — Yes; oral 5–10 mg daily courses for 5–10 days are the standard approach for abnormal uterine bleeding and audits in Austria report strong symptom control.
- How often do injectable contraceptives need to be given? — Depo‑Provera is given as 150 mg IM every 3 months and Depo‑SubQ as 104 mg SQ every 3 months, with an advised interval of 12–13 weeks.
- Do injectables affect bone health? — Long‑term use of injectable depot contraceptives can reduce bone mineral density and monitoring is recommended, particularly if use continues beyond about two years.
- Where can I get Provera and will my social insurance cover it? — Provera is prescription‑only and Sozialversicherung may reimburse indicated uses, and pharmacies can advise on eligibility and cost.
Data highlight: recommended injection intervals are 150 mg IM every 3 months or 104 mg SQ every 3 months for contraceptive effectiveness.
Guidelines For Correct Use
How should patients store and use Provera, and what should they do if a dose or injection is missed?
- Storage: store tablets at or below 25–30°C and keep away from children.
- Injectables: store between 15–30°C, protect from light and do not freeze.
- Missed Oral Dose: take as soon as remembered if still the same day; otherwise skip—do not double up.
- Missed Injection: give as soon as possible and advise backup contraception as appropriate.
Best‑practice counselling includes writing clear dosing instructions on the Rezept and in E‑Medikation, advising on missed doses, side‑effect monitoring and arranging bone density checks for long‑term injectable users.
Pharmacies in Austria commonly provide a short printed leaflet in German and offer follow‑up calls or referral pathways to specialists when needed.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 5-7 days |
| Melbourne | Victoria | 5-7 days |
| Brisbane | Queensland | 5-7 days |
| Perth | Western Australia | 5-7 days |
| Adelaide | South Australia | 5-7 days |
| Canberra | Australian Capital Territory | 5-7 days |
| Hobart | Tasmania | 5-7 days |
| Darwin | Northern Territory | 5-9 days |
| Gold Coast | Queensland | 5-7 days |
| Newcastle | New South Wales | 5-9 days |
| Wollongong | New South Wales | 5-9 days |
| Geelong | Victoria | 5-9 days |
| Cairns | Queensland | 5-9 days |
| Townsville | Queensland | 5-9 days |
| Bendigo | Victoria | 5-9 days |
